Estimation of radiation dosimetry for ^sup 68^Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer

Introduction: This study was performed to estimate the human radiation dosimetry for [68Ga]Ga-HBED-CC (PSMA-11) (68Ga PSMA-11). Methods: Under an RDRC-approved research protocol, we evaluated the biodistribution and pharmacokinetics of 68Ga PSMA-11 with serial PET imaging following intravenous admin...

Full description

Saved in:
Bibliographic Details
Published in:Nuclear medicine and biology 2017-03, Vol.46, p.32
Main Authors: Green, Mark A, Eitel, Jacob A, Fletcher, James W, Mathias, Carla J, Tann, Mark A, Gardner, Thomas, Koch, Michael O, Territo, Wendy, Polson, Heather, Hutchins, Gary D
Format: Article
Language:English
Subjects:
Acetic acid
Cancer
Computed tomography
Dosimeters
Dosimetry
Image acquisition
Injection
Intravenous administration
Kidneys
Lymph nodes
Metastases
Patients
Pelvis
Pharmacokinetics
Pharmacology
Positron emission
Prostate cancer
Radiation
Radiation dosimetry
Radioactivity
Tomography
Urine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: This study was performed to estimate the human radiation dosimetry for [68Ga]Ga-HBED-CC (PSMA-11) (68Ga PSMA-11). Methods: Under an RDRC-approved research protocol, we evaluated the biodistribution and pharmacokinetics of 68Ga PSMA-11 with serial PET imaging following intravenous administration to nine prostate cancer patients in whom clinical [11C]acetate PET/CT exams had been independently performed under Expanded Access IND 118,204. List-mode imaging was performed over the initial 0-10 min post-injection with the pelvis in the field-of-view. Whole-body images were acquired, pelvis-to-head, at 15, 60, and 90-min post-injection. Additional images of the pelvis were acquired at 40-min and 115-min, and voided urine collected from each subject at 48-min and 120-min post-injection. Radiation dosimetry estimates were calculated from these data using the OLINDA software package. Results: Renal uptake was high and relatively invariant, ranging from 11% to 14% of the injected dose between 15 and 90-min post-injection. Radioactivity collected in the voided urine accounted for 14% of the injected dose over a period of 120-min. Lymph nodes and skeletal metastases suspicious for prostate cancer recurrence were detected in a greater number of patients using 68Ga PSMA-11 than using 11C-acetate. Conclusion: Kidneys are the critical organ following 68Ga PSMA-11 administration, receiving an estimated dose of 0.413 mGy/MBq. Advances in knowledge and implications for patient care: This study confirms that the kidneys will be the critical organ following intravenous administration of 68Ga PSMA-11, and provided data consistent with the expectation that 68Ga PSMA-11 will be superior to [11C]acetate for defining sites of recurrence in prostate cancer patients presenting with biochemical relapse.
ISSN:0969-8051
1872-9614